Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

نویسندگان

  • Sophie Vallet
  • Sylvie Larrat
  • Syria Laperche
  • Hélène Le Guillou-Guillemette
  • Florence Legrand-Abravanel
  • Françoise Bouchardeau
  • Adeline Pivert
  • Cécile Henquell
  • Audrey Mirand
  • Elisabeth André-Garnier
  • Valérie Giordanengo
  • Gisèle Lagathu
  • Vincent Thibault
  • Caroline Scholtes
  • Evelyne Schvoerer
  • Catherine Gaudy-Graffin
  • Sarah Maylin
  • Pascale Trimoulet
  • Etienne Brochot
  • Sébastien Hantz
  • Joël Gozlan
  • Anne-Marie Roque-Afonso
  • Patrick Soussan
  • Jean-Christophe Plantier
  • Charlotte Charpentier
  • Stéphane Chevaliez
  • Philippe Colson
  • Vincent Mackiewicz
  • Lina Aguilera
  • Sylvain Rosec
  • Stéphanie Gouriou
  • Nelly Magnat
  • Françoise Lunel-Fabiani
  • Jacques Izopet
  • Patrice Morand
  • Christopher Payan
  • Jean-Michel Pawlotsky
چکیده

Hepatitis C virus (HCV) protease inhibitor resistance-associated substitutions are selected during triple-therapy breakthrough. This multicenter quality control study evaluated the expertise of 23 French laboratories in HCV protease inhibitor resistance genotyping. A panel of 12 well-defined blinded samples comprising two wild-type HCV strains, nine transcripts from synthetic NS3 mutant samples or from clinical strains, and one HCV RNA-negative sample was provided to the participating laboratories. The results showed that any laboratory with expertise in sequencing techniques should be able to provide reliable HCV protease inhibitor resistance genotyping. Only a 0.7% error rate was reported for the amino acid sites studied. The accuracy of substitution identification ranged from 75% to 100%, depending on the laboratory. Incorrect results were mainly related to the methodology used. The results could be improved by changing the primers and modifying the process in order to avoid cross-contamination. This study underlines the value of quality control programs for viral resistance genotyping, which is required prior to launching observational collaborative multicenter studies on HCV resistance to direct-acting antiviral agents.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

In order to assess the human immunodeficiency virus type 1 (HIV-1) drug resistance mutation profiles and evaluate the distribution of the genetic subtypes in the state of Rio de Janeiro, Brazil, blood samples from 547 HIV-1 infected patients failing antiretroviral (ARV) therapy, were collected during the years 2002 and 2003 to perform the viral resistance genotyping at the Renageno Laboratory f...

متن کامل

The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.

Specific inhibitors of hepatitis C virus (HCV) replication that target the NS3/4A protease (e.g., VX-950) or the NS5B polymerase (e.g., R1479/R1626, PSI-6130/R7128, NM107/NM283, and HCV-796) have advanced into clinical development. Treatment of patients with VX-950 or HCV-796 rapidly selected for drug-resistant variants after a 14-day monotherapy treatment period. However, no viral resistance w...

متن کامل

The Prevalence of Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infections among β-thalassemia Major: A Multicenter Survey in Lorestan, West of Iran

Background: Although regular frequent blood transfusion improves overall survival of multi-transfused patients like β-thalassemic ones, it carries a definite risk of infection with blood-borne viruses such as viral hepatitis. This study was done to determine seropositivity of hepatitis B virus (HBV), hepatitis C virus (HCV), and Human Immunedeficiency Virus (HIV) infections among β-th...

متن کامل

Protease inhibitor-based therapy for hepatitis C virus infection-why wait?

JSG The chance of clearing the virus and achieving a sustained virologic response (SVR) nearly doubled with the addition of these protease inhibitors. This improvement gave many people in the field of medicine a sense of renewal, as we finally have new agents to add to the interferon and ribavirin regimen that was the standard treatment for hepatitis C virus (HCV) infection for more than 10 years.

متن کامل

Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors

Background.  Hepatitis C virus (HCV) genotype 1 is the most prevalent worldwide. Subtype 1a, compared with 1b, shows lower response rates and higher propensity to select for drug resistance to NS3 and selected NS5A and nonnucleoside NS5B inhibitors. Two distinct clades of subtype 1a have been described. Methods.  Using Bayesian methodology, we performed a time-scaled phylogeny reconstruction of...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of clinical microbiology

دوره 51 5  شماره 

صفحات  -

تاریخ انتشار 2013